Universal asynchronous receiver-transmitter

Corner Growth Acquisition Corp. 2 Announces Extension of Expiration Time of Tender Offer for Its Class A Ordinary Shares

Retrieved on: 
Friday, December 16, 2022
Banking, Professional Services, Finance, TRON, Transfer, Tender offer, Letter, Investment Company Act of 1940, Annual report, Mini-tender offer, Security (finance), Tender, Universal asynchronous receiver-transmitter, Schedule, Acquisition, Letter of transmittal, COVID-19, Redemption

Corner Growth Acquisition Corp. 2 (NASDAQ: TRONU, TRON, TRONW) (Corner Growth or the Company) announced that it has extended the Expiration Time of its previously announced tender offer to purchase and redeem its Class A Ordinary Shares (the Shares) at a purchase price of $10.21 per share (the Tender Offer).

Key Points: 
  • Corner Growth Acquisition Corp. 2 (NASDAQ: TRONU, TRON, TRONW) (Corner Growth or the Company) announced that it has extended the Expiration Time of its previously announced tender offer to purchase and redeem its Class A Ordinary Shares (the Shares) at a purchase price of $10.21 per share (the Tender Offer).
  • Accordingly, the Company is extending the Expiration Time in order to permit shareholders to withdraw shares they have previously tendered.
  • Corner Growth shareholders who have already tendered their ordinary shares do not need to re-tender their shares or take any other action as a result of the extension of the Expiration Time of the Tender Offer.
  • Corner Growth shareholders may withdraw shares they have previously tendered at any time prior to the extended Expiration Time of the Tender Offer.

F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research

Retrieved on: 
Monday, November 7, 2022
Patient, Private Securities Litigation Reform Act, Universal asynchronous receiver-transmitter, Population, Securities Exchange Act of 1934, University, Research, Seven Seas, CNS, TIME, Annual report, Clinical Cancer Research, Technology, SEC, Company, Infrared spectroscopy correlation table, American Association for Cancer Research, GLOBE, Sino Biopharmaceutical Limited, Schedule, MD Anderson Cancer Center, Forward-looking statement, PSLRA, DCR, Drug development, Cancer, Drug discovery, Maintenance, Nasdaq, Letter, Terminology, Anaplastic thyroid cancer, Personal Information Agent, PD-L1, Immunotherapy, American Association, Therapy, Time, CD137, Patent, COMMON, Safety, Downregulation and upregulation, IO, Pharmacology, NASDAQ, Risk, Association, Communication, Pharmaceutical industry, Vaccine

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecific antibodies for immunotherapy so more people with cancer can live longer and improved lives, today announced the publication of safety and efficacy results from Phase 1 trial of FS118 in patients with advanced cancer and PD-L1 resistance in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Key Points: 
  • Phase 1 data published in Clinical Cancer Research demonstrate that FS118 has the potential to overcome cancer immune resistance given the prolonged pharmacodynamic activity, said Louis Kayitalire, Chief Medical Officer of F-star.
  • We look forward to generating additional data and leveraging our bispecific approach to provide therapies for patients with advanced cancer.
  • Weekly administration was well tolerated, with no dose-limiting toxicities (DLTs), and no serious adverse events (SEAs) relating to FS118.
  • In the Phase 1 clinical trial, FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg.

F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, August 11, 2022
CEO, GLOBE, SEC, Cancer, Clinical trial, Research, Communication, Annual report, Patient, TIME, G&A, Securities Exchange Act of 1934, Terminology, American Association, Risk, CNS, Schedule, Technology, Annual general meeting, Private Securities Litigation Reform Act, Patent, Nasdaq, HKEX, Safety, Personal Information Agent, Immunotherapy, THE, Schedule TO, IO, Drug discovery, Forward-looking statement, Letter, Sino Biopharmaceutical Limited, PD-1, Holocene, Therapy, Acquisition, Takeda, Drug development, License, AACR, LAG-3, Maintenance, Head, Pembrolizumab, Time, Association, Universal asynchronous receiver-transmitter, COMMON, CD137, F-star, Neck, Company, Twitter, NASDAQ, TILS, PSLRA, American Association for Cancer Research, LinkedIn, Fine chemical, Pharmaceutical industry, Vaccine, Cryptocurrency

Second Quarter 2022 Financial Summary:

Key Points: 
  • Second Quarter 2022 Financial Summary:
    Cash and cash equivalents were $53.0 million as of June 30, 2022, compared to $78.5 million at December 31, 2021.
  • R&D expenses were $8.7 million for the quarter ended June 30, 2022, compared to $8.3 million for the corresponding quarter in 2021.
  • G&A expenses were $7.5 million for the quarter ended June 30, 2022, compared to $6.5 million for the second quarter 2021.
  • F-star will not be hosting a conference call to discuss Q2 2022 financial results or corporate update in light of the pending transaction with invoX Pharma announced on June 23, 2022.

Gold Standard Ventures Announces Securityholder Approval of the Plan of Arrangement at Special Meeting and Provides Transaction Update

Retrieved on: 
Tuesday, August 9, 2022
Meeting, Consideration, Letter of transmittal, Minority, Forward-looking statement, NYSE, Letter, Legislation, GLOBE, SEC, TSX, OLA, Company, Proxy, Transaction, GSV, American, Acquisition, Circular, Nature, Shareholder, Gold standard, News, Gold, Carlin Unconformity, Law of the United Kingdom, Supreme court, NYSE American, SEDAR, Universal asynchronous receiver-transmitter, Security (finance), Court

The special resolution approving the Transaction was approved by (i) 98.08% of the votes cast by Gold Standard’s shareholders (the “Shareholders”) present in person or represented by proxy and entitled to vote at the Meeting; (ii) 98.21% of the votes cast by Shareholders, holders of options (“Optionholders”) and holders of restricted share units (“RSU Holders”, and together with the Shareholders and Optionholders, the “Securityholders”) of Gold Standard, voting as a single class, present in person or represented by proxy and entitled to vote at the Meeting; and (iii) 98.06% of votes cast by Shareholders other than votes attached to Gold Standard shares required to be excluded pursuant to Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions.

Key Points: 
  • In addition, RSU Holders will receive the Consideration for each Gold Standard Share received following the settlement of their restricted share units in accordance with the Plan of Arrangement.
  • Following completion of the Transaction, the Gold Standard Shares will be delisted from the TSX and NYSE American.
  • Gold Standard is developing the South Railroad Project, an open pit, heap leach gold project located in Elko County, Nevada.
  • The project is part of a +21,000 hectare land package on the Carlin Trend, and is 100% owned or controlled by Gold Standard.

invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.

Retrieved on: 
Thursday, August 4, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Personal Information Agent, Sino Biopharmaceutical Limited, CD137, Security (finance), Annual report, Acquisition, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Letter, LLP, Marketing, Sino, PJT Partners, Shearman & Sterling, NASDAQ, Communication, THE, HKEX, TIME, Computershare, Schedule, CNS, U.S. Securities and Exchange Commission, Safety, Maintenance, President's Pay Agent, Technology, Research, Drug development, Time, COMMON, Forward-looking statement, Universal asynchronous receiver-transmitter, Cancer, Therapy, R, Drug discovery, Schedule TO, P.C, Morgan Stanley, Eastern Time Zone, Degenerative disease, Patent, Risk, Immunotherapy, SEC, Fine chemical, Online shopping, Pharmaceutical industry, Bookkeeping

The tender offer is now scheduled to expire at 05:00 p.m., Eastern Time, on September 19, 2022, unless it is further extended.

Key Points: 
  • The tender offer is now scheduled to expire at 05:00 p.m., Eastern Time, on September 19, 2022, unless it is further extended.
  • The tender offer was previously scheduled to expire at one minute after 11:59 P.M., Eastern time, on August 3, 2022.
  • The tender offer is being extended in order to allow additional time for the satisfaction of the regulatory conditions to the offer.
  • All terms and conditions of the tender offer remain unchanged during the extension period.

Universal Logistics Holdings, Inc. Commences Self Tender Offer to Purchase up to 100,000 Shares

Retrieved on: 
Friday, May 13, 2022
Bangladesh Securities and Exchange Commission, Company, Universal, Letter, Tender, Multimedia, View, NASDAQ, Solution, Transport, Time, Forward-looking statement, Board, Universal asynchronous receiver-transmitter, Eastern Time Zone, Board of directors, Computershare, Security (finance)

A modified "Dutch auction" tender offer allows shareholders to indicate how many shares and at what price or prices they wish to tender their shares within the specified price range.

Key Points: 
  • A modified "Dutch auction" tender offer allows shareholders to indicate how many shares and at what price or prices they wish to tender their shares within the specified price range.
  • All shares tendered at prices higher than the purchase price will not be purchased and will be promptly returned to shareholders.
  • The tender offer is not conditioned upon any minimum number of shares being tendered; however, the tender offer is subject to a number of other terms and conditions.
  • The information in this press release describing Universal Logistics Holdings, Inc.'s tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares of Universal Logistics Holdings, Inc.'s common stock in the tender offer.

Performance Shipping Inc. Announces Extension of Its Offer to Exchange up to 4,066,181 Common Shares for Shares of Series B Convertible Cumulative Perpetual Preferred Stock

Retrieved on: 
Thursday, January 13, 2022
U.S. Securities and Exchange Commission, SERIES, Forward-looking statement, Indian stock exchange, Universal asynchronous receiver-transmitter, TO, THE, Record, SEC, Petroleum, COVID-19, Letter, NASDAQ, GLOBE, Letter of transmittal, Insurance, Pandemic, Ownership, TIME, Goal, Phrase, Company, Schedule TO, Epidemic, Schedule, Accident, Coronavirus, Transport, Security (finance), Risk management, Aframax

The extended expiration date of the offer to exchange is 5:00 p.m.,New York Citytime, on January 27, 2022, unless the offer is extended or withdrawn.

Key Points: 
  • The extended expiration date of the offer to exchange is 5:00 p.m.,New York Citytime, on January 27, 2022, unless the offer is extended or withdrawn.
  • Performance Shipping Inc. is a global provider of shipping transportation services through its ownership of Aframax tankers.
  • The information in this press release describing Performance Shipping Inc.s exchange offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Performance Shipping Inc.s securities in the exchange offer.
  • Shareholders are urged to carefully read all of these materials prior to making any decision with respect to the exchange offer.

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Retrieved on: 
Saturday, December 25, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Medication, Wall Street, Letter, Roche, Nasdaq, Communication, Technology, Disease, Person, Pain, Form, Eli Lilly, Hart–Scott–Rodino Antitrust Improvements Act, Tax, Neurodegeneration, RNA interference, Tissue, Perception, Letter of transmittal, Acquisition, Sumathi Best Television Current Reporting Award, SEC, Novo Nordisk, Health, Schedule, Forward-looking statement, HSR, Eastern Time Zone, Liver, Company, Research, Nature, FDA, Universal asynchronous receiver-transmitter, Pharmaceutical industry, Security (finance), Risk management

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Novo Nordisks cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.

Key Points: 
  • Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Novo Nordisks cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.
  • The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer.
  • Unless the tender offer is extended, the offer and withdrawal rights will expire at 5:00 p.m., Eastern Time, on December 27, 2021.
  • In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Novo Nordisk and Dicerna file annual, quarterly and current reports and other information with the SEC.

Performance Shipping Inc. Commences Offer to Exchange Up to 4,066,181 Common Shares for Shares of Series B Convertible Cumulative Perpetual Preferred Stock

Retrieved on: 
Monday, December 20, 2021
Goal, GLOBE, Letter, Legislation, Indian stock exchange, Ownership, Record, Pandemic, Insurance, Petroleum, Schedule, Security (finance), Phrase, U.S. Securities and Exchange Commission, Transport, COVID-19, THE, TIME, NASDAQ, Computershare, Private Securities Litigation Reform Act, Series, Forward-looking statement, TO, Epidemic, Company, Coronavirus, SEC, Universal asynchronous receiver-transmitter, SERIES, Accident, Public relations, Aframax

The exchange offer will expire at the end of the day, 5:00 P.M., New York City Time, on January 21, 2022, unless extended or withdrawn.

Key Points: 
  • The exchange offer will expire at the end of the day, 5:00 P.M., New York City Time, on January 21, 2022, unless extended or withdrawn.
  • as the depositary for the exchange offer and Georgeson LLC as the information agent.
  • Copies of the Offer to Exchange and the related Letter of Transmittal are being mailed to the Companys shareholders.
  • The information in this press release describing Performance Shipping Inc.s exchange offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Performance Shipping Inc.s Common Shares in the exchange offer.

Diana Shipping Inc. Commences Self Tender Offer To Purchase Up To 3,529,411 Shares

Retrieved on: 
Monday, November 22, 2021
Grain, Public expenditure, Security (finance), Insurance, Coronavirus, Perception, Phrase, Company, Achievement, NYSE, Transport, LIBOR, Compliance, New, Board of directors, SEC, FCPA, Contract, U.S. Securities and Exchange Commission, 100,000, COVID-19, Coal, Eastern Time Zone, Record, Health insurance coverage in the United States, Marshall Islands, Tender, GLOBE, Letter, Board, Ownership, Accident, Diana (ship), Universal asynchronous receiver-transmitter, Computershare, DSX, Risk management

Specific instructions and an explanation of the terms and conditions of the tender offer are contained in the Offer to Purchase and related materials that are being mailed to shareholders.

Key Points: 
  • Specific instructions and an explanation of the terms and conditions of the tender offer are contained in the Offer to Purchase and related materials that are being mailed to shareholders.
  • Diana Shipping Inc. is a global provider of shipping transportation services through its ownership of dry bulk vessels.
  • The information in this press release describing Diana Shipping Inc.s tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares of Diana Shipping Inc.s common stock in the tender offer.
  • The tender offer is being made only pursuant to the Offer to Purchase and the related materials that Diana Shipping Inc. is distributing to its shareholders, as they may be amended or supplemented.